Aims: To quantify the effect of liraglutide on systolic blood pressure (SBP) and pulse in patients with type 2 diabetes (T2D), and assess the influence of covariates on observed SBP reductions.
Methods: A patient-level pooled analysis of six phase 3, randomized trials was conducted.
Results: The analysis included 2792 randomized patients. In the intention-to-treat population (n=2783), mean [±SE] SBP reductions from baseline with liraglutide 1.2 mg (2.7 [0.8] mmHg) and 1.8 mg (2.9 [0.7] mmHg) once daily were significantly greater than with placebo (0.5 [0.9] mmHg; P=0.0029 and P=0.0004, respectively) after 26 weeks, and were evident after 2 weeks. Liraglutide was also associated with significantly greater SBP reductions than glimepiride and, at a dose of 1.8 mg, insulin glargine and rosiglitazone. SBP reductions with liraglutide weakly correlated with weight loss (Pearson's correlation coefficient: 0.08-0.12; P≤0.0148). No dependence of these reductions on concomitant antihypertensive medications was detected (P=0.1304). Liraglutide 1.2 and 1.8 mg were associated with mean increases in pulse of 3 beats per minute (bpm), versus a 1 bpm increase with placebo (P<0.0001 for each dose versus placebo).
Conclusions: Liraglutide reduces SBP in patients with T2D, including those receiving concomitant antihypertensive medication.
Trial registration: ClinicalTrials.gov NCT00294723 NCT00318422 NCT00318461 NCT00331851 NCT00333151 NCT00518882.
Keywords: Blood pressure; Hypertension; Liraglutide; Type 2 diabetes.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.